Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 11/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 10/20 | 1.00 |
| ▸ | ACHE | P22303 | 2/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 2/20 | 1.00 |
| ▸ | CDK1 | P06493 | 2/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 2/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 2/20 | 1.00 |
| ▸ | CDK2 | P24941 | 2/20 | 1.00 |
| ▸ | CCNA1 | P78396 | 2/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 2/20 | 1.00 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 1.00 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | DYRK3 | O43781 | 1/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Harmine SCHEMBL30510974 | 1.00 | MAOA (1.00) | MAOADYRK1AACHECCNB2CDK1 | |
| Harmine SCHEMBL292955 | 1.00 | MAOA (1.00) | MAOADYRK1AACHECCNB2CDK1 | |
| Harmine SCHEMBL9481427 | 1.00 | MAOA (1.00) | MAOADYRK1AACHECCNB2CDK1 | |
| Harmine SCHEMBL29941920 | 1.00 | MAOA (1.00) | MAOADYRK1AACHECCNB2CDK1 | |
| Harmine SCHEMBL1469013 | 0.98 | KLK7 (1.00) | MAOADYRK1AACHECCNB2CDK1 | |
| Harmine SCHEMBL16099771 | 0.98 | MAOA (0.97) | MAOADYRK1AACHECCNB2CDK1 | |
| Harmine SCHEMBL30726913 | 0.98 | KLK7 (1.00) | MAOADYRK1AACHECCNB2CDK1 | |
| Harmine SCHEMBL31500130 | 0.97 | KLK7 (0.97) | MAOADYRK1AACHECCNB2CDK1 | |
| Harmine SCHEMBL669625 | 0.97 | KLK7 (0.97) | MAOADYRK1AACHECCNB2CDK1 | |
| Harmine SCHEMBL4907423 | 0.97 | KLK7 (0.97) | MAOADYRK1AACHECCNB2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4351506-B1 | LIPID CRYSTALLINE COMPOSITIONS WITH ENHANCED STABILITY FOR TOPICAL DELIVERY OF ACTIVE AGENT COMBINATIONS | ANKH LIFE SCIENCES LTD (IE) | 2026-04-01 | — | — | EP | claimed |
| EP-2926119-B1 | METHOD OF MARKING OF MATERIAL, MARKED MATERIAL AND METHOD FOR AUTHENTICATING A MATERIAL | SICPA HOLDING SA (CH) | 2023-02-22 | — | — | EP | claimed |
| US-20230039704-A1 | N-(FURAN-2-YLMETHYL)-7H-PURIN-6-AMINE FOR TREATMENT OF CIRCADIAN RHYTHM DISEASES, DISORDERS AND DYSFUNCTIONS | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2023-02-09 | — | — | US | claimed |
| WO-2022265117-A1 | METHOD FOR PRODUCING MULTINUCLEATED MEGAKARYOCYTE WITH ENHANCED PLATELET PRODUCTION CAPABILITY, METHOD FOR PRODUCING PLATELETS, METHOD FOR PRODUCING PLATELET PREPARATION, AND METHOD FOR PRODUCING BLOOD PREPARATION | 株式会社メガカリオン | 2022-12-22 | — | — | WO | claimed |
| US-12636253-B2 | Modified release compositions of nafamostat and methods of using same | Ensysce Biosciences Inc. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260115182-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | CHILDRENS MEDICAL CENTER (US) | 2026-04-30 | — | — | US | disclosed |
| US-12599578-B2 | Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof | Ensysce Biosciences Inc. (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4705460-A1 | APOE-ACTIVATING NONCODING RNA (ERNA) AND USES THEREOF | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12558358-B2 | N-(furan-2-ylmethyl)-7H-purin-6-amine for treatment of circadian rhythm diseases, disorders and dysfunctions | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2026-02-24 | — | — | US | disclosed |
| US-20260007643-A1 | HIGHLY SOLUBLE FORMULATIONS OF HARMINE | RECONNECT LABS AG (CH) | 2026-01-08 | — | — | US | disclosed |
| WO-2025119975-A1 | A METHOD FOR SYNTHESIS OF HARMINE | RECONNECT LABS AG (CH) | 2025-06-12 | — | — | WO | disclosed |
| EP-4561527-A2 | HIGHLY SOLUBLE FORMULATIONS OF HARMINE | Reconnect Labs AG (CH) | 2025-06-04 | — | — | EP | disclosed |
| WO-2022115798-A2 | COMPOSITIONS AND METHODS FOR TREATING MIGRAINE | WESANA HEALTH INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022115539-A2 | MODULATING TRANSCRIPTIONAL CONDENSATES | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-06-02 | — | — | WO | disclosed |
| CN-114464912-A | Battery cooling assembly and manufacturing method thereof | 英威达纺织（英国）有限公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-108495816-B | High charge density metalloaluminophosphate molecular sieves | 环球油品公司 | 2022-05-03 | — | — | CN | disclosed |
| CN-114129603-A | Medicine for delaying senility and its application | 云南农业大学 | 2022-03-04 | — | — | CN | disclosed |
| CN-114133390-A | Harmine derivative and preparation method and application thereof | 新疆医科大学 | 2022-03-04 | — | — | CN | disclosed |
| CN-114133390-A | Harmine derivative and preparation method and application thereof | 新疆医科大学 | 2022-03-04 | — | — | CN | disclosed |
| CN-114085446-A | Creep-resistant composite material and preparation method thereof | 四川大学 | 2022-02-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007643-A1 | HIGHLY SOLUBLE FORMULATIONS OF HARMINE | SLC6A2, SLC7A1, DLST | MAOA 160/4885DYRK1A 85/4885ACHE 1550/4885 |
| US-20260115182-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | POT1, TERT, BRCA1 | MAOA 3036/4885DYRK1A 4256/4885ACHE 4410/4885 |
| US-12636253-B2 | Modified release compositions of nafamostat and methods of using same | SORD, SLC5A1, CRH | MAOA 681/4885DYRK1A 438/4885ACHE 180/4885 |
| US-12599578-B2 | Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof | OPRK1, OPRL1, OPRM1 | MAOA 113/4885DYRK1A 3590/4885ACHE 264/4885 |
| US-12558358-B2 | N-(furan-2-ylmethyl)-7H-purin-6-amine for treatment of circadian rhythm diseases, disorders and dysfunctions | PER2, CRY1, TPMT | MAOA 1229/4885DYRK1A 3478/4885ACHE 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.